[go: up one dir, main page]

AR053596A1 - Forma polimorfa ii de tanaproget - Google Patents

Forma polimorfa ii de tanaproget

Info

Publication number
AR053596A1
AR053596A1 ARP060101668A ARP060101668A AR053596A1 AR 053596 A1 AR053596 A1 AR 053596A1 AR P060101668 A ARP060101668 A AR P060101668A AR P060101668 A ARP060101668 A AR P060101668A AR 053596 A1 AR053596 A1 AR 053596A1
Authority
AR
Argentina
Prior art keywords
degree
tanaproget
polymorph
lacks
tanaproget polymorph
Prior art date
Application number
ARP060101668A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR053596A1 publication Critical patent/AR053596A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Procesos para preparar la Forma II del polimorfo de tanaproget, composiciones farmacéuticas que incluyen a la Forma II del polimorfo de tanaproget, la Forma II micronizada del polimorfo de tanaproget, y procesos para convertir la Forma II en la Forma I de tanaproget. También se proporcionan métodos de contracepcion, terapia de reemplazo hormonal, estimulacion de la ingesta de alimentos y tratar o prevenir los fibroides miometriales uterinos, hipertrofia prostática benigna, enfermedad neoplásica benigna y maligna, sangrado disfuncional leiomioma uterino, endometriosis, síndrome de ovario policístico, o carcinomas y adenocarcinomas que comprende administrar la Forma II polimorfica a un sujeto mamífero. Reivindicacion 1: Una Forma II de polimorfo de tanaproget que tiene: (a) un termograma de calorimetría por exploracion diferencial que carece de un pico endotérmico de 230 degree C; y (b) un patron de difraccion de rayos X que carece de picos en 2theta de 6,6 degree , 10,3 degree , 14,4 degree , 19,8 degree , 23,8 degree , 26,3 degree y 29,1 degree .
ARP060101668A 2005-04-28 2006-04-26 Forma polimorfa ii de tanaproget AR053596A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67573705P 2005-04-28 2005-04-28

Publications (1)

Publication Number Publication Date
AR053596A1 true AR053596A1 (es) 2007-05-09

Family

ID=36954854

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101668A AR053596A1 (es) 2005-04-28 2006-04-26 Forma polimorfa ii de tanaproget

Country Status (11)

Country Link
US (4) US7759341B2 (es)
EP (1) EP1874763A2 (es)
JP (2) JP2008539258A (es)
CN (1) CN101166736B (es)
AR (1) AR053596A1 (es)
AU (1) AU2006241125B2 (es)
BR (1) BRPI0610433A2 (es)
CA (1) CA2603807A1 (es)
MX (1) MX2007013469A (es)
TW (1) TW200716621A (es)
WO (1) WO2006116526A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2383525T3 (es) 2003-11-05 2012-06-21 Sarcode Bioscience Inc. Moduladores de la adhesión celular
BRPI0610431A2 (pt) 2005-04-28 2012-10-23 Wyeth Corp composição farmacêutica, processo para preparar uma composição, cápsula, e, kit farmacêutico
US7767668B2 (en) * 2005-04-28 2010-08-03 Wyeth Llc Micronized tanaproget, compositions, and methods of preparing the same
WO2007030153A2 (en) * 2005-04-28 2007-03-15 Wyeth Compositions containing micronized tanaproget
MX2007013469A (es) * 2005-04-28 2008-01-22 Wyeth Corp Forma ii polimorfa de tanaproget.
TW200716137A (en) 2005-06-09 2007-05-01 Wyeth Corp Tanaproget compositions containing ethinyl estradiol
CA2710293A1 (en) 2007-12-20 2009-07-02 Teva Women's Health, Inc. Dosage regimens and pharmaceutical compositions and packages for emergency contraception
US20110237605A1 (en) * 2010-03-26 2011-09-29 Eric Phillips Molecular Crystal of (4-(1,8-Naphthyridin-2-YL)Piperidin-1-YL)Pyrimidine Derivative
CN104364239B (zh) 2012-06-13 2017-08-25 霍夫曼-拉罗奇有限公司 二氮杂螺环烷烃和氮杂螺环烷烃
EP4406950A3 (en) * 2012-07-25 2025-04-23 Bausch + Lomb Ireland Limited Lfa-1 inhibitor and polymorph thereof
CA2878442A1 (en) 2012-09-25 2014-04-03 F. Hoffmann-La Roche Ag Hexahydropyrrolo[3,4-c]pyrrole derivatives and related compounds as autotaxin (atx) inhibitors and as inhibitors of the lysophosphatidic acid (lpa) production for treating e.g. renal diseases
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
PE20160845A1 (es) 2013-11-26 2016-09-10 Hoffmann La Roche Nuevo octahidro-ciclobuta[1,2-c;3,4-c']dipirrol-2-ilo
EA032357B1 (ru) 2014-03-26 2019-05-31 Ф. Хоффманн-Ля Рош Аг Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
HUE046820T2 (hu) 2014-03-26 2020-03-30 Hoffmann La Roche Biciklusos vegyületek autotaxin (ATX) és lizofoszfatidsav (LPA) termelésgátlókként
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
MX377277B (es) 2015-09-04 2025-03-07 Hoffmann La Roche Derivados de fenoximetilo.
RU2725138C2 (ru) 2015-09-24 2020-06-30 Ф. Хоффманн-Ля Рош Аг Новые бициклические соединения в качестве двойных ингибиторов аутотаксина (atx)/карбоангидразы (ca)
BR112018006034A2 (pt) 2015-09-24 2018-10-09 Hoffmann La Roche compostos bicíclicos como inibidores de atx
MA42923A (fr) 2015-09-24 2021-04-28 Hoffmann La Roche Composés bicycliques comme inhibiteurs mixtes de atx/ca
WO2017050732A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
CN110382484B (zh) 2017-03-16 2022-12-06 豪夫迈·罗氏有限公司 新的作为atx抑制剂的二环化合物
KR20190129924A (ko) 2017-03-16 2019-11-20 에프. 호프만-라 로슈 아게 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서 유용한 헤테로환형 화합물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU766801B2 (en) * 1999-05-04 2003-10-23 Wyeth Cyclothiocarbamate derivatives as progesterone receptor modulators
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
EP1531824A4 (en) 2002-06-25 2005-09-21 Wyeth Corp CYCLOTHIOCARBAMATIVE DERIVATIVES AS PR MODULATORS AND THEIR USE IN TREATING SKIN DISORDERS
TW200404548A (en) 2002-06-25 2004-04-01 Wyeth Corp Pharmaceutical composition containing cyclothiocarbamate derivatives in treatment of hormone-related conditions
US8399013B2 (en) * 2003-06-26 2013-03-19 Poly-Med, Inc. Partially absorbable fiber-reinforced composites for controlled drug delivery
PA8631101A1 (es) 2004-04-27 2006-09-08 Wyeth Corp Proceso de acoplamiento para la generacion de derivados reactivos de pirrol-2-carbonitrilo n-sustituidos con contenido de boro para producir biarilos
WO2005104711A2 (en) 2004-04-27 2005-11-10 Wyeth Purification of progesterone receptor modulators
ES2380219T3 (es) 2004-08-13 2012-05-09 Wyeth Llc Metabolitos, derivados de tanaproget, y sus utilizaciones
MX2007013469A (es) * 2005-04-28 2008-01-22 Wyeth Corp Forma ii polimorfa de tanaproget.
WO2007030153A2 (en) 2005-04-28 2007-03-15 Wyeth Compositions containing micronized tanaproget
US7786297B2 (en) 2005-04-28 2010-08-31 Wyeth Llc Purified form of tanaproget
BRPI0610431A2 (pt) * 2005-04-28 2012-10-23 Wyeth Corp composição farmacêutica, processo para preparar uma composição, cápsula, e, kit farmacêutico
US7767668B2 (en) 2005-04-28 2010-08-03 Wyeth Llc Micronized tanaproget, compositions, and methods of preparing the same
TW200716137A (en) 2005-06-09 2007-05-01 Wyeth Corp Tanaproget compositions containing ethinyl estradiol

Also Published As

Publication number Publication date
WO2006116526A3 (en) 2007-06-28
AU2006241125B2 (en) 2012-07-05
US20120115858A1 (en) 2012-05-10
CN101166736A (zh) 2008-04-23
WO2006116526A8 (en) 2007-08-16
JP2008539258A (ja) 2008-11-13
US8114869B2 (en) 2012-02-14
US7968709B2 (en) 2011-06-28
US20100267715A1 (en) 2010-10-21
MX2007013469A (es) 2008-01-22
TW200716621A (en) 2007-05-01
US7759341B2 (en) 2010-07-20
CN101166736B (zh) 2013-02-06
US20060247235A1 (en) 2006-11-02
AU2006241125A1 (en) 2006-11-02
EP1874763A2 (en) 2008-01-09
CA2603807A1 (en) 2006-11-02
US20110212953A1 (en) 2011-09-01
WO2006116526A2 (en) 2006-11-02
BRPI0610433A2 (pt) 2010-11-23
JP2014088385A (ja) 2014-05-15

Similar Documents

Publication Publication Date Title
AR053596A1 (es) Forma polimorfa ii de tanaproget
CY1110017T1 (el) Μικρονισμενη ταναπρογετη και συνθεσεις που περιεχουν αυτην
AR056328A1 (es) TANAPROGET MICRONIZADO, COMPOSICIONES Y MÉTODOS PARA SU PREPARACIoN
MXPA03011985A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
CY1106610T1 (el) Μεθοδος για την προληψη ή την θεραπευτικη αντιμετωπιση καλοηθων γυναικολογικων διαταραχων
CO4810234A1 (es) Vacunas para el tratamiento de virus papiloma humano
ES2152671T3 (es) Derivados de progesterona sustituidos en posicion 21 como nuevos agentes antiprogestacionales.
Arsenyan et al. Selenium analogues of raloxifene as promising antiproliferative agents in treatment of breast cancer
JP2008539258A5 (es)
TW200731969A (en) Use of progesterone receptor modulators
CR6742A (es) Acidos malonamicos y derivados de los mismos como ligandos de receptor tiroideo
CN104185622A (zh) 6,7-二氢-5h-苯并[7]轮烯衍生物、其制备方法、包含所述6,7-二氢-5h-苯并[7]轮烯衍生物的药物制剂及其用于制备药物的用途
RU2016119135A (ru) Производные пиразолопиримидона или пирролотриазона, способ их получения и их фармацевтические применения
DK1874278T3 (da) Sammensætninger indeholdende mikroniseret tanaproget
NZ515353A (en) Cyclothiocarbamate derivatives as progesterone receptor modulators
DE602005019905D1 (de) -modulatoren
CR9598A (es) Moduladores no esteroides de receptor de progesterona
PE20090167A1 (es) Sintesis y caracterizacion de la forma iii polimorfica de 4-(2-(4,4-dimetil-2-oxooxazolidin-3-il)tiazol-4-il)benzonitrilo
WO2008109055A3 (en) Cyanopyrrole sulfonamides useful for modulation of the progesterone receptor
CY1109919T1 (el) Παραγωγα της ινδολης που ειναι χρησιμα σα ρυθμιστες του υποδοχεα της προγεστερονης
DOP2006000147A (es) Uso de modulares no esteroides de receptores de progesterona.
JP5735122B2 (ja) 抗癌活性を有するベンズアミド誘導体並びにその製造方法および使用
PE20081803A1 (es) Sintesis y caracterizacion de la forma ii polimorfica de 4-(2-(4,4-dimetil-2-oxooxazolidin-3-il)tiazol-4-il)benzonitrilo
UY28284A1 (es) Alquil-estra-1,3,5 (10)-trienos 8b-vinil-11b-(w-sustituidos)
RU2016100028A (ru) Полиморфные формы икотиниба и их применения

Legal Events

Date Code Title Description
FA Abandonment or withdrawal